title: We should prohibit warfarin in idiopathic pulmonary fibrosis.
authors: 1 Aix Marseille Université Marseille, France.
authors: Khuder
authors: K
authors: Alagha
authors: Veronique
authors: V
authors: Secq
authors: Laurie
authors: L
authors: Pahus
authors: Tunde
authors: T
authors: Sofalvi
authors: Alain
authors: A
authors: Palot
authors: Arnaud
authors: A
authors: Bourdin
authors: Pascal
authors: P
authors: Chanez
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy*; D017809:Fatal Outcome; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000150:complications*; D008297:Male; D008875:Middle Aged; D013924:Thrombophlebitis / Q000150:complications* / Q000188:drug therapy*; D014859:Warfarin / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D014859:Warfarin